Amid widespread confusion over when the HIV prevention pill will go generic, a spokeswoman for Teva on Monday told STAT that the company has reached a confidential settlement controlling when it can enter the marketplace.
That spokeswoman, Elizabeth DeLuca, declined to say when Teva will launch its generic version of the drug currently sold by Gilead as Truvada, or how much it will charge.
The Food and Drug Administration last week approved Teva’s bid to sell the first generic pill for the HIV prevention method known as pre-exposure prophylaxis, or PrEP. That news initially brought excitement and hope in the HIV/AIDS community that the new option would usher in lower prices.
About the Author Reprints
